# Bio-Path Holdings, Inc. (BPTH)

> Source: Nexqual · https://nexqual.com/BPTH · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Bio-Path Holdings, Inc. (BPTH), nexqual.com/BPTH" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–0.11 · market cap $15K · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -99.6% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$10.9M | -$10.4M | -$13.9M | -$15.8M | -$12.0M | -$8.6M |
| Net income | -$10.9M | -$10.4M | -$13.9M | -$16.1M | -$9.9M | -$8.7M |
| EPS (diluted) | -$56.60 | -$31.00 | -$38.12 | -$33.63 | -$4.12 | — |
| Free cash flow | — | -$10.0M | -$15.1M | — | — | — |
| Cash + short-term investments | $13.8M | $23.8M | $10.4M | $1.1M | $1.2M | — |
| Total debt | $0K | $0K | $0K | $0K | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Mar 31, 2026)
Earnings yield -57624.76%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -99.6% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -99.7% | -92.1% |
| Volatility (annualized) | 739.4% | 298.9% |
| Max drawdown | -99.9% (Oct 2025→Sep 2026) | -100.0% (Oct 2021→Sep 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/BPTH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in BPTH's own 10-K filed 2025-03-27 (https://www.sec.gov/Archives/edgar/data/1133818/000155837025003837/bpth-20241231x10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Roth Capital Partners | "On August 3, 2023, we entered into a placement agency agreement with Roth Capital Partners, LLC relating to a best efforts public offering of an aggregate of 175,000 shares of its common stock, together with warrants to …" |
| Partner | Diagonal Lending | "On March 6, 2025, we entered into a securities purchase agreement with 1800 Diagonal Lending LLC, a Virginia limited liability company (the "Lender"), an accredited investor, for the issuance and sale of a promissory not…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2025-12-31) | — | — | — | $0 | — |
| Current fiscal year (ends 2025-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |